HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 24, 2009--
Global Pharmaceuticals, the generic products division of Impax
Laboratories, Inc. (NASDAQ: IPXL), today announced their cooperation in
awarding a modest grant to Myasthenia Gravis Alliance, also known as
Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non
profit membership corporation, incorporated in the State of New York. A
portion of the grant will fund The Alliance Fellowship for Myasthenia
Gravis Research, at the University of California, Davis, under the
direction of Dr. Robert Fairclough, Faculty Researcher/ Principal
Investigator. The remainder of the grant will help defer the cost of The
Circle News and other operating items.
Myasthenia Gravis is a chronic, sometimes fatal autoimmune neuromuscular
disease in which communication between nerve and muscle is impaired,
causing muscle fatigue. The disease is highly misdiagnosed. A
neurologist is recommended for diagnosis. Global Pharmaceuticals is a
leading distributor of pyridostigmine bromide, a key agent used in the
treatment of Myasthenia Gravis.
Christopher Mengler, R.Ph., divisional president of Global
Pharmaceuticals said: “We are pleased to assist the Myasthenia Gravis
Alliance with a grant to further research and awareness of this disease.
We recognize the need for research that will hopefully lead to improved
quality of life and eventually result in a cure.”
“Our primary goal is to ensure that the proper and appropriate
information is forwarded to our myasthenic patients as soon as they are
diagnosed,” Executive Director, Debra Santulli-Barone declared, “since
the first two years of diagnosis is crucial.”
Ms. Santulli-Barone continued: “I am so grateful to Global
Pharmaceuticals for listening to our needs and providing a grant. This
will give our members newfound hope. We can now launch a monthly MG
Series Support Meeting to address topics such as, 'How to Deal with Your
Spouse/Family While Living with MG, Cold Weather Tips, and, Your Options
with Medication.'”
About Myasthenia Gravis Alliance
Myasthenia Gravis Alliance has been a staple in the myasthenic community
for over 20 years. The charitable nonprofit organization was formed to
serve patient needs, promote public awareness, provide support for
patients, while continuing to fund research when possible.
Myasthenia Gravis Alliance; Myasthenia Gravis Foundation of Greater New
York, Inc. (www.MGdirect.org)
meetings will be held at 61 Gramercy Park North, Ste. 605, New York, NY
10010. For further information, call Debra Santulli-Barone at (212)
533-7005.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical
company applying its formulation expertise and drug delivery technology
to the development of controlled-release and specialty generics in
addition to the development of branded products. Impax markets its
generic products through its Global Pharmaceuticals division and markets
its branded products through the Impax Pharmaceuticals division.
Additionally, where strategically appropriate, Impax has developed
marketing partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a full
range of capabilities in its Hayward and Philadelphia facilities. For
more information, please visit the Company's Web site at: www.impaxlabs.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6107428&lang=en
Source: Impax Laboratories, Inc.
Impax Laboratories, Inc.
Mark
Donohue, Sr. Director Investor Relations
(215) 933-3526
www.impaxlabs.com